Sickle Cell Disease Trial, Recruiting (NCT04484272)

Sickle Cell Disease Trial, Recruiting NCT04484272 Sponsor: University of Florida Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT04484272 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Sickle Cell Disease (SCD), including types such as HbSS, HbSC, HbS-beta-0 thalassemia, or HbS-beta+ thalassemia
You have experienced moderate to severe pain (rated more than 3 out of 10) related to your SCD within the last 24 hours
You use opioid pain medications either when needed or on a regular, ongoing basis
You can speak and read English
You are 18 years of age or older

Who may not be able to join:

You are legally blind
You are physically unable to complete the study procedures (confirm with trial site)
You have already taken part in a previous relaxation/distraction intervention feasibility study run by this research team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Miriam O. Ezenwa, University of Florida

Phone: 352-273-6520

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04484272

Sponsor: University of Florida

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 352-273-6520

More information: https://clinicaltrials.gov/study/NCT04484272

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Sickle Cell Disease (SCD), including types such as HbSS, HbSC, HbS-beta-0 thalassemia, or HbS-beta+ thalassemia
You have experienced moderate to severe pain (rated more than 3 out of 10) related to your SCD within the last 24 hours
You use opioid pain medications either when needed or on a regular, ongoing basis
You can speak and read English
You are 18 years of age or older

Who may not be able to join:

You are legally blind
You are physically unable to complete the study procedures (confirm with trial site)
You have already taken part in a previous relaxation/distraction intervention feasibility study run by this research team

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Florida

Registry

ClinicalTrials.gov

Start date

29 April 2021

Est. completion

30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Stress intensity scale; Pain intensity scale; Opioid use

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov